Effectiveness and Safety of Edaravone Dexborneol in Acute Ischemic Stroke

Inclusion Criteria: * Age≥18 years old； * Clinically diagnosed as acute ischemic stroke； * Time from symptom onset to admission≤14 days (symptom onset time is defined as last known well time)； * Pre-stroke mRS ≤1； * Have been informed of the content of the informed consent form and agree to participate. Exclusion Criteria: * Acute intracranial hemorrhagic diseases confirmed by images: parenchymal hemorrhage, epidural hematoma, subdural hematoma, ventricular hemorrhage, subarachnoid hemorrhage, etc. * Patients who are pregnant or lactating and who are planned to become pregnant within 90 days; * Patients with severe renal failure (eGFR\<30ml/min); * Patients with concurrent malignancy or severe systemic disease with an estimated survival of less than 90 days; * Patients with severe mental disorders or unable to complete the informed consent and follow-up due to dementia; * Patients who are judged unsuitable for participation in the study.